[Federal Register Volume 78, Number 20 (Wednesday, January 30, 2013)]
[Notices]
[Pages 6329-6330]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-01976]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Initial Review

    The meeting announced below concerns Evaluation of Treatments and 
Services Provided to People with

[[Page 6330]]

Duchenne Muscular Dystrophy (DMD), FOA DD13-002, initial review.
    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the aforementioned meeting:

    Time and Date: 11:00 a.m.-5:00 p.m., March 28, 2013 (Closed).
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance 
with provisions set forth in Section 552b(c)(4) and (6), Title 5 
U.S.C., and the Determination of the Director, Management Analysis 
and Services Office, CDC, pursuant to Public Law 92-463.
    Matters To Be Discussed: The meeting will include the initial 
review, discussion, and evaluation of applications received in 
response to ``Evaluation of Treatments and Services Provided to 
People with Duchenne Muscular Dystrophy (DMD), FOA DD13-002, initial 
review.''
    Contact Person for More Information: M. Chris Langub, Ph.D., 
Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F-
46, Atlanta, Georgia 30341, Telephone: (770) 488-3585, [email protected].
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention 
and the Agency for Toxic Substances and Disease Registry.


Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2013-01976 Filed 1-29-13; 8:45 am]
BILLING CODE 4163-18-P